30
total announcements
IOLCP.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹5,979 Cr
P/E (TTM)
35.6
P/E (Forward)
19.6
EPS (TTM)
₹5.72
52W Low
₹67.19
52W High
₹224.00
Dividend Yield
0.51%
Beta
0.54
Price / Book
3.3
Debt / Equity
7.5
Revenue (TTM)
₹2,524 Cr
Gross Margin
35.39%
Operating Margin
10.86%
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which show a profit before exceptional items and tax of ₹86.77 crore.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the publication of the Notice of the 39th Annual General Meeting and e-voting information in newspapers, as well as the availability of the AGM Notice and Integrated Annual Report on the company's website and the website of Central Depository Services (India) Limited.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the schedule of an analyst/investor conference call to discuss the financial performance of the Company for the quarter ended 30th June 2026.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 02, 2026.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the publication of a newspaper advertisement for its 39th Annual General Meeting, which will be held through Video Conferencing on September 2, 2026.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has received approval from the National Medical Products Administration (NMPA), China for its API product 'Clopidogrel Bisulfate'. This approval is in addition to the existing Certificate of Suitability (CEP) held by the company, strengthening its regulatory portfolio and expanding its access to the Chinese pharmaceutical market.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of physical share certificates and substitution of the depository's name as the registered owner.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the reaffirmation of its credit rating by CARE Ratings Limited.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited announced the publication of newspaper notices concerning two key investor-focused initiatives. These initiatives include a "Special Window for Transfer-cum-Dematerialisation of Physical Shares" and IEFP’s ‘Saksham Niveshak’ campaign. The primary objective is to facilitate shareholders in claiming unpaid or unclaimed dividends and updating their Know Your Customer (KYC) details. This announcement is significant for investors holding physical shares or those with outstanding dues, providing a crucial opportunity to regularize their holdings and ensure compliance.